Temasek, Sequoia Capital back $90m round in China’s JW Therapeutics

A biological testing process underway at a personal products lab. Photo: Bloomberg

A consortium of leading global investors including Temasek and Sequoia Capital China has joined the $90-million Series A financing round of Shanghai-based biotech startup JW Therapeutics, according to an official announcement.

Continue reading this story with a subscription to DealStreetAsia.


Contact us for corporate subscriptions at